Latest News and Press Releases

LianBio to receive total upfront consideration of $350 millionLianBio Board of Directors to conduct strategic review of business SHANGHAI and PRINCETON, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) --...

上海和新泽西普林斯顿, Oct. 24, 2023 (GLOBE NEWSWIRE) --...

EXPLORER-CN研究数据在欧洲心脏病学会年会（ESC）Late-Breaking专场上以口头报告方式公布试验数据同步发表于《JAMA Cardiology》Mavacamten（玛伐凯泰）在中国梗阻性肥厚型心肌病（oHCM）患者的Valsalva 左心室流出道峰值压差、左心室流出道梗阻、临床症状、健康状况、心脏生物标志物和心脏结构等方面均显示出改善研究证实，先前确定的...

EXPLORER-CN data presented in oral late-breaking science session at ESC 2023Data from the trial published simultaneously in JAMA CardiologyMavacamten demonstrated improvement in Valsalva LVOT peak...

Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic...

中国国家药品监督管理局（NMPA）正在对mavacamten的新药上市申请（NDA）进行优先审评Mavacamten在中国有症状的梗阻性肥厚型心肌病（oHCM）患者中开展的EXPLORER-CN...

SHANGHAI, China and PRINCETON, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...

上海和新泽西州普林斯顿, Aug. 04, 2023 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克:LIAN)，一家致力于为中国和其他亚洲主要市场的患者带来创新药物的生物技术公司，于今日宣布，评估公司旗下SHP2抑制剂BBP-398联合阿斯利康公司的奥希替尼治疗EGFR突变阳性非小细胞肺癌（NSCLC）患者的I期临床试验已完成首例患者给药。 ...

上海和新泽西州普林斯顿, July 26, 2023 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克股票代码：LIAN）的合作伙伴 Tarsus Pharmaceuticals于昨日宣布，美国食品药品监督管理局（FDA）已批准其产品XDEMVY™ （0.25% 洛替拉纳滴眼液）用于蠕形螨睑缘炎的治疗。XDEMVY（曾用名...

SHANGHAI, China and PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Tarsus Pharmaceuticals (Tarsus), announced yesterday that the U.S. Food and Drug...